• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

Research Briefing on Azoniaspironortropanol Chloride (CAS: 3464-71-9): Recent Advances and Applications

Azoniaspironortropanol chloride (CAS: 3464-71-9) is a quaternary ammonium compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a muscarinic acetylcholine receptor (mAChR) antagonist, with particular focus on its selectivity and binding affinity. This research briefing synthesizes the latest findings on this compound, highlighting its mechanism of action, pharmacological properties, and emerging applications in drug development.

One of the key advancements in the study of Azoniaspironortropanol chloride is its characterization as a selective antagonist for the M2 subtype of mAChRs. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that the compound exhibits high binding affinity (Ki = 2.3 nM) for M2 receptors, with significantly lower affinity for other mAChR subtypes. This selectivity makes it a valuable tool for investigating the physiological roles of M2 receptors and for developing targeted therapies for conditions such as bradycardia and chronic obstructive pulmonary disease (COPD).

In addition to its receptor-binding properties, recent research has explored the structural determinants of Azoniaspironortropanol chloride's activity. X-ray crystallography and molecular docking studies have revealed that the spiro-nortropane moiety and the positively charged quaternary nitrogen are critical for its interaction with the M2 receptor's allosteric site. These insights have informed the design of novel derivatives with improved pharmacokinetic profiles, as reported in a 2024 Bioorganic & Medicinal Chemistry Letters article.

Another promising area of investigation is the potential use of Azoniaspironortropanol chloride in neurological disorders. Preclinical studies have shown that the compound can modulate cholinergic neurotransmission in the hippocampus, suggesting possible applications in Alzheimer's disease and other cognitive impairments. However, further research is needed to evaluate its blood-brain barrier permeability and long-term safety profile.

From a synthetic chemistry perspective, recent efforts have focused on optimizing the production of Azoniaspironortropanol chloride. A 2023 patent application disclosed a novel, high-yield synthesis route that reduces the number of steps and improves overall efficiency. This development is expected to facilitate larger-scale production for both research and potential clinical use.

In conclusion, Azoniaspironortropanol chloride (3464-71-9) represents a versatile compound with significant potential in both basic research and drug development. Its selective M2 receptor antagonism, well-characterized structure-activity relationship, and ongoing synthetic improvements position it as a valuable asset in the chemical biology and pharmaceutical toolkit. Future research directions may include the exploration of its therapeutic potential in other disease areas and the development of more potent analogs with enhanced selectivity and bioavailability.

• 41447-16-9((+)-N-Methylallosedridine)
• 120-29-6(Tropine)
• 135-97-7(Pseudotropine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)